{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:25Z","timestamp":1772120065271,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172720"],"award-info":[{"award-number":["82172720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403791"],"award-info":[{"award-number":["82403791"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Province University Youth Innovation Team Program","award":["2024KJJ027"],"award-info":[{"award-number":["2024KJJ027"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH459"],"award-info":[{"award-number":["ZR2024QH459"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSCO-Nav HER2-related Solid Tumors Research Foundation","award":["Y-2022HER2AZMS-0291"],"award-info":[{"award-number":["Y-2022HER2AZMS-0291"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12149-025-02057-0","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T11:53:48Z","timestamp":1746878028000},"page":"862-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular imaging using 18F-FDG PET\/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA\u2013IIIB NSCLC"],"prefix":"10.1007","volume":"39","author":[{"given":"Kaiyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"1","key":"2057_CR1","first-page":"82","volume":"4","author":"H Zhai","year":"2015","unstructured":"Zhai H, Zhong W, Yang X, Wu YL. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015;4(1):82\u201393.","journal-title":"Transl Lung Cancer Res"},{"issue":"Suppl 5","key":"2057_CR2","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","volume":"21","author":"L Crin\u00f2","year":"2010","unstructured":"Crin\u00f2 L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v103-115.","journal-title":"Ann Oncol"},{"issue":"21","key":"2057_CR3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"10","key":"2057_CR4","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, et al. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol. 2023;9(10):1348\u201355.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2057_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15(5):709\u201340.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2057_CR6","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1097\/JS9.0000000000000496","volume":"109","author":"Y Chen","year":"2023","unstructured":"Chen Y, Qin J, Wu Y, Lin Q, Wang J, Zhang W, et al. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis. Int J Surg. 2023;109(9):2794\u2013807.","journal-title":"Int J Surg"},{"key":"2057_CR7","doi-asserted-by":"crossref","unstructured":"Zhang L, Huang J, Wu J, Li Q, Hou L, et al. Clinical utility of [(18)F]FDG PET\/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer. Eur Radiol. 2023;33(12):8564\u201372.","DOI":"10.1007\/s00330-023-09910-8"},{"issue":"8","key":"2057_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jtho.2021.03.029","volume":"16","author":"A Pataer","year":"2021","unstructured":"Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, et al. Evaluation of pathologic response in lymph nodes of patients with lung cancer receiving neoadjuvant chemotherapy. J Thorac Oncol. 2021;16(8):1289\u201397.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2057_CR9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","volume":"34","author":"X Liu","year":"2021","unstructured":"Liu X, Sun W, Wu J, Feng Y, Mao L, Chen M, et al. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Mod Pathol. 2021;34(11):1990\u20138.","journal-title":"Mod Pathol"},{"issue":"3","key":"2057_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487-502.e415.","journal-title":"Cell"},{"issue":"1","key":"2057_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5152\/TurkThoracJ.2017.16025","volume":"18","author":"GE Akta\u015f","year":"2017","unstructured":"Akta\u015f GE, Sar\u0131kaya A, Demir SS. Diffusely increased splenic fluorodeoxyglucose uptake in lung cancer patients. Turk Thorac J. 2017;18(1):6\u201310.","journal-title":"Turk Thorac J"},{"issue":"4","key":"2057_CR12","first-page":"559","volume":"47","author":"S Pr\u00e9vost","year":"2006","unstructured":"Pr\u00e9vost S, Boucher L, Lariv\u00e9e P, Boileau R, B\u00e9nard F. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med. 2006;47(4):559\u201365.","journal-title":"J Nucl Med"},{"issue":"3","key":"2057_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00259-007-0628-6","volume":"35","author":"C Van de Wiele","year":"2008","unstructured":"Van de Wiele C, VandeVyver F, Debruyne C, Philipp\u00e9 J, van Meerbeeck JP. FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels. Eur J Nucl Med Mol Imaging. 2008;35(3):519\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2057_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cllc.2016.07.001","volume":"18","author":"JW Lee","year":"2017","unstructured":"Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic significance of FDG uptake of bone marrow on PET\/CT in patients with non-small-cell lung cancer after curative surgical resection. Clin Lung Cancer. 2017;18(2):198\u2013206.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"2057_CR15","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1007\/s00330-016-4568-z","volume":"27","author":"JW Lee","year":"2017","unstructured":"Lee JW, Seo KH, Kim ES, Lee SM. The role of (18)F-fluorodeoxyglucose uptake of bone marrow on PET\/CT in predicting clinical outcomes in non-small cell lung cancer patients treated with chemoradiotherapy. Eur Radiol. 2017;27(5):1912\u201321.","journal-title":"Eur Radiol"},{"issue":"2","key":"2057_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1148\/radiol.2019190357","volume":"293","author":"SA Mattonen","year":"2019","unstructured":"Mattonen SA, Davidzon GA, Benson J, Leung ANC, Vasanawala M, Horng G, et al. Bone Marrow and tumor radiomics at (18)F-FDG PET\/CT: impact on outcome prediction in non-small cell lung cancer. Radiology. 2019;293(2):451\u20139.","journal-title":"Radiology"},{"issue":"1","key":"2057_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2967\/jnumed.121.262361","volume":"63","author":"RD Seban","year":"2022","unstructured":"Seban RD, Champion L, Muneer I, Synn S, Schwartz LH, Dercle L. Potential theranostic role of bone marrow glucose metabolism on baseline (18)F-FDG PET\/CT in metastatic melanoma. J Nucl Med. 2022;63(1):166.","journal-title":"J Nucl Med"},{"issue":"1","key":"2057_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12890-022-01951-x","volume":"22","author":"Y Yan","year":"2022","unstructured":"Yan Y, Wang X, Liu C, Jia J. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. BMC Pulm Med. 2022;22(1):166.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2057_CR19","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2057_CR20","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1111\/1759-7714.14562","volume":"13","author":"ZY Chen","year":"2022","unstructured":"Chen ZY, Fu R, Tan XY, Yan LX, Tang WF, Qiu ZB, et al. Dynamic (18) F-FDG PET\/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13(17):2524\u201331.","journal-title":"Thorac Cancer"},{"issue":"1","key":"2057_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40644-024-00772-x","volume":"24","author":"R Guo","year":"2024","unstructured":"Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, et al. The utility of (18)F-FDG PET\/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer. Cancer Imaging. 2024;24(1):120.","journal-title":"Cancer Imaging"},{"issue":"10","key":"2057_CR22","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1007\/s00330-023-09922-4","volume":"33","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Chen ZY, Huang JJ, Shao D. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET\/CT with postoperative pathology. Eur Radiol. 2023;33(10):6625\u201335.","journal-title":"Eur Radiol"},{"key":"2057_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101725","volume":"35","author":"X Chen","year":"2023","unstructured":"Chen X, Bai G, Zang R, Song P, Bie F, Huai Q, et al. Utility of (18)F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Transl Oncol. 2023;35: 101725.","journal-title":"Transl Oncol"},{"issue":"19","key":"2057_CR24","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2057_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2057_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335-346.e333.","journal-title":"J Allergy Clin Immunol"},{"issue":"44","key":"2057_CR27","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353.","journal-title":"Oncogene"},{"issue":"10","key":"2057_CR28","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128(10):4654\u201368.","journal-title":"J Clin Invest"},{"issue":"9","key":"2057_CR29","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1172\/JCI69741","volume":"123","author":"JR Doherty","year":"2013","unstructured":"Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685\u201392.","journal-title":"J Clin Invest"},{"key":"2057_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"ZH Wang","year":"2021","unstructured":"Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine. 2021;73: 103627.","journal-title":"EBioMedicine"},{"key":"2057_CR31","doi-asserted-by":"publisher","first-page":"1004351","DOI":"10.3389\/fimmu.2022.1004351","volume":"13","author":"P Jin","year":"2022","unstructured":"Jin P, Bai M, Liu J, Yu J, Meng X. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer. Front Immunol. 2022;13:1004351.","journal-title":"Front Immunol"},{"issue":"5","key":"2057_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ejrad.2011.01.126","volume":"81","author":"X Qu","year":"2012","unstructured":"Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 1\u2078FDG-PET-CT, 1\u2078FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007\u201315.","journal-title":"Eur J Radiol"},{"key":"2057_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102895","volume":"148","author":"L Corrales","year":"2020","unstructured":"Corrales L, Rosell R, Cardona AF, Mart\u00edn C, Zatarain-Barr\u00f3n ZL, Arrieta O. Lung cancer in never smokers: the role of different risk factors other than tobacco smoking. Crit Rev Oncol Hematol. 2020;148: 102895.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:25:38Z","timestamp":1757168738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02057-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6238047\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute (No. SDZLEC2021-189) and informed consent was obtained from all individual participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}